Biologics Distribution for Orthopedic Practices in New York, NY

Vendor qualification for orthopedic practices

Orthopedic groups and surgery centers that bring in tissue allografts or exosome products typically run a vendor qualification step before the first order: confirming who processes the tissue, what testing accompanies each lot, and what documentation is produced at release.

Tissue used in Precision Biologics' Wharton's jelly products is recovered by trained, licensed personnel and processed within 48 hours of recovery, in a process the supplier describes as following FDA regulations and AATB and AABB guidelines. Each lot carries a unique identifier, and a sample from that lot is sent to a third-party laboratory for sterility testing before the lot is released.

Practices that want to confirm a supplier's registration or licensure status can request supporting documentation directly rather than relying on website claims; Precision Biologics makes registration and licensure documentation available to verified accounts on request.

NPI-verified accounts

Every Precision Biologics account is opened for a licensed professional and checked against an NPI number before product ships, matching how the rest of the industry treats HCT/P and biologic drug distribution: orders go to licensed buyers, not the public.

A practice administrator can start account setup with practice information and the ordering physician's NPI; a Precision Biologics team member confirms the number against the NPPES registry before activating the account.

Receiving cold-chain shipments in the Northeast

Cryopreserved products ship overnight on dry ice in validated shipping containers and are stored at -80 degrees Celsius once received, so New York practices need a freezer capable of holding that temperature and a staff member assigned to log receipt against the packing list.

Because shipments move overnight rather than same day, many practices build a one-day lead time into their ordering calendar. Lyophilized formats are shelf-stable and skip that cold-chain step, which some practices use to simplify intake at satellite locations. Either way, Precision Biologics asks every location to record lot numbers at the patient-record level so use is traceable back to the original lot.

Confirming regulatory posture before you order

Whether a particular orthopedic use of a Wharton's jelly or exosome product fits a practice's own regulatory framework is a determination for the practice and its counsel, not something Precision Biologics advises on. We recommend confirming your intended use and any state-specific requirements directly with the New York State medical board and your own legal counsel.

Precision Biologics can set up a peer-to-peer call between a practice's physician and a Precision Biologics team member to walk through sourcing and testing documentation, but these calls do not cover clinical use, dosing, or procedures.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.